You are here: Industry Insights > Market News > Bharat Biotech signs supply deal with Brazil for 20 million doses of COVAXIN

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

SG-DJ10 Capsule and Tablet Sample Checkweigher

NADP+

NMN

Ceritinib (LDK378) CAS:1032900-25-6

SG-JN10 0.1mg Tablet Capsule Check Weigher

β-Nicotinamide Adenine Dinucleotide (NAD+)

Bharat Biotech signs supply deal with Brazil for 20 million doses of COVAXIN

expresspharmaMarch 01, 2021

Tag: Bharat Biotech , brazil , Covaxin

Favorites

Bharat Biotech International confirmed that the company has signed an agreement with Brazil for supply of 20 million doses of COVAXIN.

It has signed an agreement for the delivery of COVAXIN during Q2 and Q3 2021.

The company informed through a statement, “The company is delighted to partner with Brazil in its battle against Covid-19 and aid its immunization program against the virus. There is a strong interest in COVAXIN from many countries around the world, and the company is fully committed to ensuring supplies promptly and efficiently.”

Previous:Sales of injectable anti-HIV therapeutics will reach $2 billion in 2029: GlobalData

Next:NATCO launches Brivaracetam tablets in India

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

Bharat Biotech signs supply deal with Brazil for 20 million doses of COVAXIN | Pharmasources.com

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

MetP Pharma AG today announced tirzepatide in a BrainDos™ formulation reduced pro-inflammatory cytokine Il-6 by more than 80% and 2-fold stronger than with aqueous tirzepatide solution.

Bharat Biotech signs supply deal with Brazil for 20 million doses of COVAXIN

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may like
More>>

Bharat Biotech signs supply deal with Brazil for 20 million doses of COVAXIN

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may likeMore>>

You may like
More>>